Does PEMIGATINIB Cause Malignant neoplasm progression? 7 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Malignant neoplasm progression have been filed in association with PEMIGATINIB (PEMAZYRE). This represents 1.0% of all adverse event reports for PEMIGATINIB.
7
Reports of Malignant neoplasm progression with PEMIGATINIB
1.0%
of all PEMIGATINIB reports
1
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From PEMIGATINIB?
Of the 7 reports, 1 (14.3%) resulted in death, 2 (28.6%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
Yes, Malignant neoplasm progression is listed as a known adverse reaction in the official FDA drug label for PEMIGATINIB.
What Other Side Effects Does PEMIGATINIB Cause?
Off label use (114)
Disease progression (103)
Death (76)
Fatigue (72)
Alopecia (53)
Hyperphosphataemia (46)
Cholangiocarcinoma (44)
Diarrhoea (42)
Constipation (37)
Drug ineffective (37)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which PEMIGATINIB Alternatives Have Lower Malignant neoplasm progression Risk?
PEMIGATINIB vs PENICILLAMINE
PEMIGATINIB vs PENICILLIN
PEMIGATINIB vs PENICILLIN G
PEMIGATINIB vs PENICILLIN G BENZATHINE
PEMIGATINIB vs PENICILLIN G PROCAINE